

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/153194 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) C07K 16/28 (2006.01)

A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/050219

(22) International Filing Date:

13 January 2022 (13.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/136,928 13 January 2021 (13.01.2021) US

(71) Applicants: **MEMORIAL SLOAN KETTERING CANCER CENTER** [US/US]; 1275 York Avenue, New York, New York 10065 (US). **TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE** [US/US]; 413 East 69th Street, Box 300, New York, New York 10021 (US).

(72) Inventors: **POIRIER, John T.**; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US). **RUDIN, Charles**; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US). **LEWIS, Jason**; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US). **KHAN, Abdul**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10065 (US). **ANDREW, David**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **CHEN, Xinlei**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **LORENZ, Ivo**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **MATSUNAGA, Hironori**; c/o Daiichi Sankyo Company, Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/153194 A1

(54) Title: ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE

(57) Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 antibody-pyrrolodiazepine derivative conjugate using the same.